Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aspirin merits testing for prevention of cervical cancer in HIV-infected women

19.01.2012
Researchers say their study is the first to show how hiv ramps up this cancer-causing pathway -- and the first to offer a potential solution

Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women.

The report, published in the current issue of journal Cancer Prevention Research, says this simple and inexpensive solution has the potential to provide enormous benefit for women in the Caribbean, Latin America and Africa, who suffer from a disproportionately high rate of cervical cancer death.

Preventive aspirin use could be especially useful in Haiti, where invasive cervical cancer is a common cause of death in HIV-infected women. The country also has the highest reported incidence of cervical cancer in the world and one of the highest HIV infection rates in the Western Hemisphere.

"These young patients -- many of whom were mothers and the sole support for their families -- had worked hard to have their HIV controlled with antiretroviral therapy, only to develop and die from cervical cancer," says the study's lead researcher, Dr. Daniel Fitzgerald, an associate professor of medicine at Weill Cornell Medical College who lived in Haiti for seven years and continues to treat HIV patients there.

Dr. Fitzgerald is a key member of the Weill Cornell Medical College Center for Global Health and directs the College's collaboration with GHESKIO, a Haitian non-governmental organization dedicated to providing clinical service, research and training in HIV/AIDS since 1980.

"The results of this collaborative effort will make a real difference for women living in one of the poorest nations in the world," he says. "It is wonderful that clinicians and scientists from different parts of the world were able to come together to address such a critical issue of care."

The researchers discovered that HIV induces expression of the COX-2/prostaglandin E2 (PGE2) inflammatory pathway in cervical tissue samples from Haitian women who were infected with HIV. The findings tie two known facts together: that HIV causes chronic inflammation; and that PGE2, which is elevated during inflammation, is linked to cancer development in a number of tumor types, including cervical cancer.

The fact that HIV ramps up production of PGE2 in cervical tissue was not known before this study, the researchers say.

This may help explain why HIV-positive women are five times more likely to develop invasive cervical cancer than HIV-negative women. It also suggests that inhibitors of the COX-2 molecule (which contributes to the production of PGE2) might break the link between HIV and cervical cancer. Aspirin is one of the cheapest and most effective COX inhibitors.

"The findings in this study provide new insights into the link between viral infection and inflammation, two known drivers of cancer development," says senior author Dr. Andrew Dannenberg, director of the Weill Cornell Cancer Center at NewYork-Presbyterian/Weill Cornell and the Henry R. Erle, M.D.–Roberts Family Professor of Medicine at Weill Cornell Medical College.

"Future studies will be needed to determine whether aspirin-like agents, known inhibitors of prostaglandin production, can reduce the risk of cervical cancer in this high-risk population," he adds.

The researchers examined levels of COX-2 and PGE-M (a stable metabolite of PGE2) in three groups of women and found increased levels of both molecules in 13 women who were co-infected with HIV and HPV. COX-2 and PGE-M were also elevated in 18 HIV-infected women with a negative HPV test and lowest in 17 HIV-negative women who also were not infected with HPV.

The findings thus demonstrate that HIV infection is associated with increased cervical COX-2 and elevated systemic PGE2 levels, says Dr. Fitzgerald. Co-infection with HPV adds to the cervical cancer risk. Future studies will seek to define the population of women that may benefit from daily use of aspirin or related inhibitors.

Dr. Fitzgerald, along with GHESKIO physician and study co-author Dr. Cynthia Riviere, initiated the clinical research program to care for and prevent cervical cancer in HIV-positive women in Haiti after they began noticing an increasing report of cases.

"The goal is to give patients in Haiti the same standard of treatment found in any cancer center," says Dr. Jeremie Arash Rafii Tabrizi, assistant professor of genetic medicine at Weill Cornell Medical College in Qatar who has treated women at the GHESKIO clinic. "We are focusing on procedures that will allow for a reduction of morbidity -- as this is a major concern in this population -- as well as a reduction of risk of recurrence."

The research was funded by the National Cancer Institute, the Fogarty International Center, and the Flight Attendant Medical Research Institute.

Other co-authors include Karl Bezak, Oksana Ocheretina, Xi Kathy Zhou, Baoheng Du, Kotha Subbaramaiah, Erin Byrt and Matthew L. Goodwin, all from Weill Cornell; Thomas C. Wright from Columbia University College of Physicians and Surgeons; and Ginger L. Milne from Vanderbilt University School of Medicine.

Dr. Dannenberg is the senior editor for Cancer Prevention Research.

The authors declare the following potential conflicts of interest: Dr. Dannenberg is a member of the Scientific Advisory Board and holds an equity interest in Tragara Pharmaceuticals Inc., a company that is developing a selective COX-2 inhibitor. Dr. Fitzgerald supervises a scholarship program for Tanzanian medical students sponsored by Pfizer Inc.

For more information, patients may call 866-NYP-NEWS.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center

NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances -- including the development of the Pap test for cervical cancer; the synthesis of penicillin; the first successful embryo-biopsy pregnancy and birth in the U.S.; the first clinical trial for gene therapy for Parkinson's disease; the first indication of bone marrow's critical role in tumor growth; and, most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian/The Allen Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit http://www.nyp.org and http://www.weill.cornell.edu

Richard Pietzak | EurekAlert!
Further information:
http://www.nyp.org
http://www.weill.cornell.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>